staphylococcal protein A (PRTX-100)
/ Protalex
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
June 10, 2021
Reaserch Advances in the Treatment of Primary Immune Thrombocytopenia--Review
(PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
- "Recently, avatrombopag and fostamatinib have been approved by the FDA for the treatment of primary ITP in adults, while new drugs such as rozanolixizumab, efgartigimod, PRTX-100, decitabine and atorvastatin have shown efficacy in early clinical trials. This review summarizes the current accepted therapies for the clinical treatment of primary ITP in adults, and briefly discuss the progress of new therapies."
Journal • Review • Hematological Disorders • Immunology • Thrombocytopenia • Thrombocytopenic Purpura
October 02, 2015
Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia
(clinicaltrials.gov)
- P1/2; N=30; Not yet recruiting; Sponsor: Protalex, Inc.
New P1/2 trial • Biosimilar • Hematological Malignancies • Immunology
November 09, 2015
Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia
(clinicaltrials.gov)
- P1/2; N=30; Recruiting; Sponsor: Protalex, Inc.; Not yet recruiting ➔ Recruiting
Enrollment open • Biosimilar • Hematological Malignancies • Immunology
July 05, 2019
PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP
(clinicaltrials.gov)
- P1/2; N=13; Terminated; Sponsor: Protalex, Inc.; N=36 ➔ 13; Active, not recruiting ➔ Terminated; Enough data has been collected to allow analysis of safety profile and risk-benefit.
Clinical • Enrollment change • Trial termination
March 25, 2019
PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP
(clinicaltrials.gov)
- P1b; N=15; Terminated; Sponsor: Protalex, Inc.; N=30 ➔ 15; Trial completion date: Dec 2018 ➔ May 2018; Recruiting ➔ Terminated; Trial primary completion date: Dec 2018 ➔ May 2018; Enough data has been collected to allow analysis of the safety profile and risk-benefit.
Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination
March 25, 2019
PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP
(clinicaltrials.gov)
- P1/2; N=36; Active, not recruiting; Sponsor: Protalex, Inc.; Recruiting ➔ Active, not recruiting; Trial primary completion date: Dec 2018 ➔ Mar 2019
Clinical • Enrollment closed • Trial primary completion date
1 to 6
Of
6
Go to page
1